Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | TP53 Y220C |
| Therapy | PC14586 |
| Indication/Tumor Type | stomach cancer |
| Response Type | predicted - sensitive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| TP53 Y220C | stomach cancer | predicted - sensitive | PC14586 | Preclinical - Cell line xenograft | Actionable | In a preclinical study, PC14586 treatment reactivated Tp53 function, resulted in 80% tumor regression after 3 weeks in cell line xenograft models of gastric cancer harboring TP53 Y220C (AACR Annual Meeting Apr 2021, Session MS.LBA01, Abstract # LB006). | detail... |
| PubMed Id | Reference Title | Details |
|---|---|---|
| PC14586: The first orally bioavailable small molecule reactivator of Y220C mutant p53 in clinical development | Full reference... |